The company is actively ... Additionally, Pfizer’s financial outlook appears promising, particularly with the potential for improved pricing and cash flow for its Paxlovid product.

for Pfizer. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Scroll through the chart ... flow increases and immune cells rush to the scene. This can result in pain, redness, or swelling at the injection site. The reaction is more common after Pfizer's ...

Pfizer is rated Zacks Rank #2 (Buy). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: While earnings growth is arguably the most superior indicator of ...